Alteogen Shares Rise 4% After Halozyme Core Patent Invalidity Ruling

Alteogen shares rose about 4% after news that a core patent held by rival Halozyme had been judged invalid. The two companies are currently engaged in a patent dispute over subcutaneous injection formulation technology, and the latest decision was interpreted as giving Alteogen a more favorable position in the dispute. The original report also noted an appeal by KOSDAQ and venture associations for high-quality companies to remain listed on KOSDAQ. The patent dispute’s progress is emerging as a direct factor for Alteogen’s share price and investor sentiment. Source: mk.co.kr